9-Hydroxyellipticine hydrochloride

Cat. No.:	HY-101775A
CAS No.:	52238-35-4
Molecular Formula:	$C_{17}H_{15}ClN_2O$
Molecular Weight:	298.77
Target:	Topoisomerase
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	9-Hydroxyellipticine hydrochloride is a inhibitor of Topo II and RyR. 9-Hydroxyellipticine hydrochloride exhibits antitumor, antioxidant and catecholamine-releasing activities. 9-Hydroxyellipticine hydrochloride exhibits IC_{50} values of 1.6 μM and 1.2 μM in Hela S-3 and 293T cells, respectively[1][2][3].
IC_{50} & Target	Topoisomerase II
In Vitro	9-Hydroxyellipticine (9HE) causes selective inhibition of p53 protein phospborylation in Lewis lung carcinoma and SW480 (human colon cancer cell line) in a concentration-dependent manner from 0.1 to 100 μM[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	9-Hydroxyellipticine (5 or 10 mg/kg, ip) results in chromosome clumping and sister chromatid exchange in murine bone marrow cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Three- to five-month-old C57B1/6 male mice[1].
Dosage:	5 or 10 mg/kg.
Administration:	IP.
Result:	Resulted in chromosome clumping, chromatid aberrations, and micronuclei formation in murine bone marrow cells.

REFERENCES

[1]. Renault G, et al. In vivo exposure to four ellipticine derivatives with topoisomerase inhibitory activity results in chromosome clumping and sister chromatid exchange in murine bone marrow cells. Toxicol Appl Pharmacol. 1987 Jun 30;89(2):281-6.

[2]. Saeki K, et al. Cardioprotective effects of 9-hydroxyellipticine on ischemia and reperfusion in isolated rat heart. Jpn J Pharmacol. 2002 May;89(1):21-8.

[3]. Naoya Sato, et al. Synthesis and in vitro Antitumor Activity of 9-Hydroxyellipticine Derivatives with Glucose Conjugation via Triazolylmethyl Succinate Linker. Heterocycle, Vol. 92, NO 4, 2016.

[4]. Ohashi M, et al. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn J Cancer Res. 1995 Sep;86(9):819-27.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA